Impact of HIV Drug Resistance on HIV/AIDS-Associated Mortality, New Infections, and Antiretroviral Therapy Program Costs in Sub–Saharan Africa

To inform the level of attention to be given by antiretroviral therapy (ART) programs to HIV drug resistance (HIVDR), we used an individual-level model to estimate its impact on future AIDS deaths, HIV incidence, and ART program costs in sub–Saharan Africa (SSA) for a range of program situations. We...

Descripción completa

Detalles Bibliográficos
Autores principales: Phillips, Andrew N., Stover, John, Cambiano, Valentina, Nakagawa, Fumiyo, Jordan, Michael R., Pillay, Deenan, Doherty, Meg, Revill, Paul, Bertagnolio, Silvia
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Oxford University Press 2017
Materias:
Brief Report
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5451603/
https://www.ncbi.nlm.nih.gov/pubmed/28329236
http://dx.doi.org/10.1093/infdis/jix089
_version_ 1783240206956101632
author Phillips, Andrew N.
Stover, John
Cambiano, Valentina
Nakagawa, Fumiyo
Jordan, Michael R.
Pillay, Deenan
Doherty, Meg
Revill, Paul
Bertagnolio, Silvia
author_facet Phillips, Andrew N.
Stover, John
Cambiano, Valentina
Nakagawa, Fumiyo
Jordan, Michael R.
Pillay, Deenan
Doherty, Meg
Revill, Paul
Bertagnolio, Silvia
author_sort Phillips, Andrew N.
collection PubMed
description To inform the level of attention to be given by antiretroviral therapy (ART) programs to HIV drug resistance (HIVDR), we used an individual-level model to estimate its impact on future AIDS deaths, HIV incidence, and ART program costs in sub–Saharan Africa (SSA) for a range of program situations. We applied this to SSA through the Spectrum-Goals model. In a situation in which current levels of pretreatment HIVDR are over 10% (mean, 15%), 16% of AIDS deaths (890 000 deaths), 9% of new infections (450 000), and 8% ($6.5 billion) of ART program costs in SSA in 2016–2030 will be attributable to HIVDR.
format Online
Article
Text
id pubmed-5451603
institution National Center for Biotechnology Information
language English
publishDate 2017
publisher Oxford University Press
record_format MEDLINE/PubMed
spelling pubmed-54516032017-06-05 Impact of HIV Drug Resistance on HIV/AIDS-Associated Mortality, New Infections, and Antiretroviral Therapy Program Costs in Sub–Saharan Africa Phillips, Andrew N. Stover, John Cambiano, Valentina Nakagawa, Fumiyo Jordan, Michael R. Pillay, Deenan Doherty, Meg Revill, Paul Bertagnolio, Silvia J Infect Dis Brief Report To inform the level of attention to be given by antiretroviral therapy (ART) programs to HIV drug resistance (HIVDR), we used an individual-level model to estimate its impact on future AIDS deaths, HIV incidence, and ART program costs in sub–Saharan Africa (SSA) for a range of program situations. We applied this to SSA through the Spectrum-Goals model. In a situation in which current levels of pretreatment HIVDR are over 10% (mean, 15%), 16% of AIDS deaths (890 000 deaths), 9% of new infections (450 000), and 8% ($6.5 billion) of ART program costs in SSA in 2016–2030 will be attributable to HIVDR. Oxford University Press 2017-05-01 2017-02-17 /pmc/articles/PMC5451603/ /pubmed/28329236 http://dx.doi.org/10.1093/infdis/jix089 Text en © The Author 2017. Published by Oxford University Press for the Infectious Diseases Society of America. http://creativecommons.org/licenses/by-nc-nd/4.0 This is an Open Access article distributed under the terms of the Creative Commons Attribution-NonCommercial-NoDerivs licence (http://creativecommons.org/licenses/by-nc-nd/4.0/), which permits non-commercial reproduction and distribution of the work, in any medium, provided the original work is not altered or transformed in any way, and that the work is properly cited. For commercial re-use, please contact journals.permissions@oup.com
spellingShingle Brief Report
Phillips, Andrew N.
Stover, John
Cambiano, Valentina
Nakagawa, Fumiyo
Jordan, Michael R.
Pillay, Deenan
Doherty, Meg
Revill, Paul
Bertagnolio, Silvia
Impact of HIV Drug Resistance on HIV/AIDS-Associated Mortality, New Infections, and Antiretroviral Therapy Program Costs in Sub–Saharan Africa
title Impact of HIV Drug Resistance on HIV/AIDS-Associated Mortality, New Infections, and Antiretroviral Therapy Program Costs in Sub–Saharan Africa
title_full Impact of HIV Drug Resistance on HIV/AIDS-Associated Mortality, New Infections, and Antiretroviral Therapy Program Costs in Sub–Saharan Africa
title_fullStr Impact of HIV Drug Resistance on HIV/AIDS-Associated Mortality, New Infections, and Antiretroviral Therapy Program Costs in Sub–Saharan Africa
title_full_unstemmed Impact of HIV Drug Resistance on HIV/AIDS-Associated Mortality, New Infections, and Antiretroviral Therapy Program Costs in Sub–Saharan Africa
title_short Impact of HIV Drug Resistance on HIV/AIDS-Associated Mortality, New Infections, and Antiretroviral Therapy Program Costs in Sub–Saharan Africa
title_sort impact of hiv drug resistance on hiv/aids-associated mortality, new infections, and antiretroviral therapy program costs in sub–saharan africa
topic Brief Report
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5451603/
https://www.ncbi.nlm.nih.gov/pubmed/28329236
http://dx.doi.org/10.1093/infdis/jix089
work_keys_str_mv AT phillipsandrewn impactofhivdrugresistanceonhivaidsassociatedmortalitynewinfectionsandantiretroviraltherapyprogramcostsinsubsaharanafrica
AT stoverjohn impactofhivdrugresistanceonhivaidsassociatedmortalitynewinfectionsandantiretroviraltherapyprogramcostsinsubsaharanafrica
AT cambianovalentina impactofhivdrugresistanceonhivaidsassociatedmortalitynewinfectionsandantiretroviraltherapyprogramcostsinsubsaharanafrica
AT nakagawafumiyo impactofhivdrugresistanceonhivaidsassociatedmortalitynewinfectionsandantiretroviraltherapyprogramcostsinsubsaharanafrica
AT jordanmichaelr impactofhivdrugresistanceonhivaidsassociatedmortalitynewinfectionsandantiretroviraltherapyprogramcostsinsubsaharanafrica
AT pillaydeenan impactofhivdrugresistanceonhivaidsassociatedmortalitynewinfectionsandantiretroviraltherapyprogramcostsinsubsaharanafrica
AT dohertymeg impactofhivdrugresistanceonhivaidsassociatedmortalitynewinfectionsandantiretroviraltherapyprogramcostsinsubsaharanafrica
AT revillpaul impactofhivdrugresistanceonhivaidsassociatedmortalitynewinfectionsandantiretroviraltherapyprogramcostsinsubsaharanafrica
AT bertagnoliosilvia impactofhivdrugresistanceonhivaidsassociatedmortalitynewinfectionsandantiretroviraltherapyprogramcostsinsubsaharanafrica

Ejemplares similares